{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:28:09Z","timestamp":1787041689264,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) frequently involves polycystic liver disease (PLD), which can impair quality of life. While genotype strongly predicts renal outcomes, determinants of hepatic cyst burden and progression remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 332 genotyped patients with ADPKD. Total liver volume was quantified on serial CT to calculate height-adjusted TLV (HtTLV) and annual percentage growth (\u0394HtTLV\/year). To reduce baseline dependency inherent to ratio-based outcomes, we additionally evaluated a log-transformed growth metric (log[HtTLV2\/HtTLV1]\/year). Associations with demographic, clinical, and medication factors were examined using multivariable linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Genotype was not associated with hepatic cyst prevalence, baseline HtTLV, or growth. Greater hepatic cyst burden (HtTLV) was independently associated with female sex, Mayo class C\u2013E, smoking history, and higher BMI. For progression, calcium channel blocker (CCB) use remained independently associated with higher growth in both \u0394HtTLV\/year and log-transformed models, whereas other antihypertensive classes were not. Baseline HtTLV was strongly associated with subsequent growth across models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cohort, clinical factors were more closely associated with PLD burden and progression than genotype. CCB exposure was consistently associated with higher hepatic growth metrics; however, because residual confounding by indication remains possible, causality cannot be inferred. Nevertheless, this association represents a clinically important hypothesis that should be evaluated in future prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02935-5","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:06:16Z","timestamp":1787040376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical rather than genetic factors predict hepatic cyst burden and growth in autosomal dominant polycystic kidney disease: a cohort study of 332 genotyped patients"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1818-4920","authenticated-orcid":false,"given":"Keiji","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2935_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2215\/CJN.00080605","volume":"1","author":"KT Bae","year":"2006","unstructured":"Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006;1:64\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2935_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","volume":"13","author":"MC Hogan","year":"2015","unstructured":"Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, et al. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015;13:155\u2013e646.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2935_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s10157-019-01830-6","volume":"24","author":"S Muto","year":"2020","unstructured":"Muto S, Ando M, Nishio S, Hanaoka K, Ubara Y, Narita I, et al. The relationship between liver cyst volume and QOL in Japanese ADPKD patients. Clin Exp Nephrol. 2020;24:314\u201322.","journal-title":"Clin Exp Nephrol"},{"key":"2935_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2019.04.018","volume":"157","author":"RMM van Aerts","year":"2019","unstructured":"van Aerts RMM, Kievit W, D\u2019Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, et al. Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease. Gastroenterology. 2019;157:481\u2013e4917.","journal-title":"Gastroenterology"},{"key":"2935_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jhep.2017.11.024","volume":"68","author":"RMM van Aerts","year":"2018","unstructured":"van Aerts RMM, van de Laarschot LFM, Banales JM, Drenth JPH. Clinical management of polycystic liver disease. J Hepatol. 2018;68:827\u201337.","journal-title":"J Hepatol"},{"key":"2935_CR6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/ndt\/gfw008","volume":"31","author":"FT Chebib","year":"2016","unstructured":"Chebib FT, Jung Y, Heyer CM, Irazabal MV, Hogan MC, Harris PC, et al. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transpl. 2016;31:952\u201360.","journal-title":"Nephrol Dial Transpl"},{"key":"2935_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s10157-005-0367-6","volume":"9","author":"S Horie","year":"2005","unstructured":"Horie S. ADPKD: molecular characterization and quest for treatment. Clin Exp Nephrol. 2005;9:282\u201391.","journal-title":"Clin Exp Nephrol"},{"key":"2935_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4:50.","journal-title":"Nat Rev Dis Primers"},{"key":"2935_CR9","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1681\/ASN.2012070650","volume":"24","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall E, Audr\u00e9zet M-P, Chen J-M, Hourmant M, Morin M-P, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24:1006\u201313.","journal-title":"J Am Soc Nephrol"},{"key":"2935_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biom13071020","author":"T Kimura","year":"2023","unstructured":"Kimura T, Kawano H, Muto S, Muramoto N, Takano T, Lu Y, et al PKD1 mutation is a biomarker for autosomal dominant polycystic kidney disease. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13071020.","journal-title":"Biomolecules"},{"key":"2935_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","volume":"343","author":"D Ravine","year":"1994","unstructured":"Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994;343:824\u20137.","journal-title":"Lancet"},{"key":"2935_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"2935_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/jhep.2003.50006","volume":"37","author":"Q Qian","year":"2003","unstructured":"Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J 3, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology. 2003;37:164\u201371.","journal-title":"Hepatology"},{"key":"2935_CR14","doi-asserted-by":"publisher","first-page":"e0144526","DOI":"10.1371\/journal.pone.0144526","volume":"10","author":"H Kim","year":"2015","unstructured":"Kim H, Park HC, Ryu H, Kim K, Kim HS, Oh K-H, et al. Clinical correlates of mass effect in autosomal dominant polycystic kidney disease. PLoS ONE. 2015;10:e0144526.","journal-title":"PLoS ONE"},{"key":"2935_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2215\/CJN.08660621","volume":"17","author":"KT Bae","year":"2022","unstructured":"Bae KT, Tao C, Feldman R, Yu ASL, Torres VE, Perrone RD, et al. Volume progression and imaging classification of polycystic liver in early autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2022;17:374\u201384.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2935_CR16","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1080\/0886022X.2021.1949348","volume":"43","author":"CB Gul","year":"2021","unstructured":"Gul CB, Yildiz A, Sag S, Oruc A, Ersoy A, Gullulu S. The effect of smoking on endothelial dysfunction in autosomal dominant polycystic kidney disease patients with preserved renal function. Ren Fail. 2021;43:1124\u20139.","journal-title":"Ren Fail"},{"key":"2935_CR17","doi-asserted-by":"publisher","unstructured":"Wei Wang JSB. Effects of smoking on ADPKD: Frequency of vascular events and concentrations of soluble CD40 ligand. Gen Med (Los Angel). 2015;03. https:\/\/doi.org\/10.4172\/2327-5146.1000175.","DOI":"10.4172\/2327-5146.1000175"},{"key":"2935_CR18","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1038\/s41440-023-01455-z","volume":"46","author":"Y Higashi","year":"2023","unstructured":"Higashi Y. Smoking cessation and vascular endothelial function. Hypertens Res. 2023;46:2670\u20138.","journal-title":"Hypertens Res"},{"key":"2935_CR19","doi-asserted-by":"publisher","first-page":"109704","DOI":"10.1016\/j.cellsig.2020.109704","volume":"73","author":"X Song","year":"2020","unstructured":"Song X, Tsakiridis E, Steinberg GR, Pei Y. Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease. Cell Signal. 2020;73:109704.","journal-title":"Cell Signal"},{"key":"2935_CR20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2215\/CJN.16871020","volume":"16","author":"KL Nowak","year":"2021","unstructured":"Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and obesity and progression of ADPKD. Clin J Am Soc Nephrol. 2021;16:908\u201315.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2935_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135700","author":"S Kashyap","year":"2020","unstructured":"Kashyap S, Hein KZ, Chini CC, Lika J, Warner GM, Bale LK, et al Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.135700.","journal-title":"JCI Insight"},{"key":"2935_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2215\/CJN.0000000000000326","volume":"19","author":"FT Chebib","year":"2024","unstructured":"Chebib FT, Nowak KL, Chonchol MB, Bing K, Ghanem A, Rahbari-Oskoui FF, et al. Polycystic kidney disease diet: what is known and what is safe: what is known and what is safe. Clin J Am Soc Nephrol. 2024;19:664\u201382.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2935_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0272-6386(97)90496-0","volume":"30","author":"T Yamaguchi","year":"1997","unstructured":"Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis. 1997;30:703\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2935_CR24","doi-asserted-by":"publisher","first-page":"40419","DOI":"10.1074\/jbc.M405079200","volume":"279","author":"T Yamaguchi","year":"2004","unstructured":"Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem. 2004;279:40419\u201330.","journal-title":"J Biol Chem"},{"key":"2935_CR25","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2024.07.009","volume":"107","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group","year":"2025","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD). Kidney Int. 2025;107:S1\u2013239.","journal-title":"Kidney Int"},{"key":"2935_CR26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/jog.15881","volume":"50","author":"K Kitamura","year":"2024","unstructured":"Kitamura K, Colli E, Azuma R, Kikuyama R, Kanai M. A phase I\/II study evaluating the pharmacokinetics, pharmacodynamics, and safety of drospirenone as an oral contraceptive in Japanese women. J Obstet Gynaecol Res. 2024;50:682\u201390.","journal-title":"J Obstet Gynaecol Res"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02935-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02935-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02935-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:06:17Z","timestamp":1787040377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02935-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":26,"alternative-id":["2935"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02935-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (ethical approval was granted by the Juntendo University Ethics Committee; IRB approval number 2019107) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}